This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at firstname.lastname@example.org or call 800-767-3771 ext. 9339.
For Immediate Release
Chicago, IL – July 30, 2012 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Laboratory Corporation of America Holdings (LH - Analyst Report), Quest Diagnostics (DGX - Analyst Report), WellPoint (WLP - Analyst Report), Humana (HUM - Analyst Report) and Cigna (CI - Analyst Report).
Get the most recent insight from Zacks Equity Research with the free Profit from the Pros newsletter: http://at.zacks.com/?id=5513
Here are highlights from Friday’s Analyst Blog:
Earnings Scorecard: LabCorp
Laboratory Corporation of America Holdings’ (LH - Analyst Report) disappointing second quarter 2012 results, released on July 19, prompted analysts to slash their estimates for the forthcoming periods, pricing in the challenges currently at play in this sector.
Second Quarter Highlights
LabCorp reported earnings per share (“EPS”) of $1.56 in the second quarter of fiscal 2012 compared with $1.20 in the year-ago quarter. Restructuring charge aside, the company recorded expenses related to acquisitions and loss on the disposal of one of its European subsidiaries and one of its joint ventures.
Adjusted EPS came in at $1.77 (excluding amortization, restructuring and other special charges), a penny behind the Zacks Consensus Estimate. Earnings, however, surpassed the previous year's adjusted EPS of $1.64.
Revenues increased 1.4% year over year to $1,423.4 million, marginally missing the Zacks Consensus Estimate of $1,440 million. The low-volume-growth environment is reflected in flat testing volume (measured by requisitions) while revenue per requisition increased a nominal 1.5%.
LabCorp narrowed its guidance for fiscal 2012. The company expects 2−3% revenue growth (previous guidance of 2−3.5%), resulting in adjusted EPS of $6.80−$7.00 ($6.75−$7.05) in the fiscal year.
In addition, guidance for operating cash flow and capital expenditure remained unchanged at $950 million and $155 million, respectively. Genzyme Genetics is expected to be slightly accretive to 2012 earnings.
For a full coverage on the earnings, read: LabCorp Misses, Narrows Guidance
Agreement of Analysts
With economic uncertainty taking a toll on the company’s performance, estimate revision trend is bearish for the next two quarters as well as the fiscals ahead. Over the last 7 days, 11 of the 17 analysts covering the stock have lowered their estimates for the third quarter of 2012, with no revisions northward. The same trend can be seen for the current fiscal year, with 12 downward revisions. None of the analysts have raised their estimates.
A continuous decline in organic volume growth, lower utilization trends and impending reimbursement cuts in 2013 are the major headwinds for LabCorp. Consequently, the company reported flat volume growth during the reported quarter with a 0.5% decline in organic volume, a disappointment from 1% growth in the first quarter.
The company also fared worse than its peer Quest Diagnostics (DGX - Analyst Report), which clocked 0.7% organic volume growth. The decline was primarily due to flattened Vitamin D test volume, which has been a growth driver historically and continued weakness in the histology category. We note that organic growth has been on a declining trend over the past few quarters – 3% in first, 2% in second, 1.2% in the third and 0.7% in the fourth quarter of fiscal 2011.
With no significant job growth in the economy or an increase in commercially insured covered lives, the company’s overall volume growth will continue to languish until the economy rebounds. Given the challenging scenario the company narrowed its growth outlook for 2012.
The reimbursement scenario is also challenging with an impending cut of approximately 5% in the clinical lab fee schedule beginning January 1, 2013. Mandatory physician fee schedule will also witness a 2% cut, effective January 1, 2013. LabCorp derives 12% and 2% of its revenues from clinical lab fee schedule and physician fee schedule, respectively.
Magnitude of Estimate Revisions
With the majority of analysts lowering their estimates for the forthcoming period, the consensus estimate for the third quarter dropped by a couple of cents to $1.75 in the past 7 days. The consensus estimate for fiscal 2012 also witnessed a drop of 5 cents to $6.95 over the last 7 days, indicative of market pessimism on the back of sluggish macroeconomic trends.
Neutral on LabCorp
LabCorp reported a disappointing second quarter with both revenues and adjusted EPS lagging the Zacks Consensus Estimates. This was followed by an overall market pessimism with the analysts scaling down expectations for the future. The low-volume-growth environment is reflected in flat testing volume while revenue per requisition increased 1.5%.
The current economic uncertainty continues to adversely affect the company. The company is also exposed to the reduction in clinical and physician lab fee schedule, effective January 2013. We do not expect any significant improvement in the situation in near future. The stock retains a Zacks #4 Rank (Sell) in the short term.
Despite these challenges, the company is working on portfolio expansion to drive its top line. The company is focusing more on the high-margin esoteric testing business, which is expected to contribute 45% of total sales in the next 3–5 years. LabCorp is also paying due attention to IT initiatives to improve physician and patient experience.
LabCorp continues to work closely with Managed Care Organizations (MCOs) by providing value added capabilities and services. We are impressed with the company extending its contract with WellPoint (WLP - Analyst Report) on a multi-year basis with stable pricing and exclusivity retained in all of the key markets. The company is also engaged in contract renewal discussions with Humana (HUM - Analyst Report), due 2012 and Cigna (CI - Analyst Report), due mid-2013.
Over the long term, we have a Neutral recommendation on LabCorp.
Want more from Zacks Equity Research? Subscribe to the free Profit from the Pros newsletter: http://at.zacks.com/?id=5515.
About Zacks Equity Research
Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.
Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.
Zacks "Profit from the Pros" e-mail newsletter provides highlights of the latest analysis from Zacks Equity Research. Subscribe to this free newsletter today: http://at.zacks.com/?id=5517
Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 by Leon Zacks. As a PhD from MIT Len knew he could find patterns in stock market data that would lead to superior investment results. Amongst his many accomplishments was the formation of his proprietary stock picking system; the Zacks Rank, which continues to outperform the market by nearly a 3 to 1 margin. The best way to unlock the profitable stock recommendations and market insights of Zacks Investment Research is through our free daily email newsletter; Profit from the Pros. In short, it's your steady flow of Profitable ideas GUARANTEED to be worth your time! Register for your free subscription to Profit from the Pros at http://at.zacks.com/?id=5518.
Visit http://www.zacks.com/performance for information about the performance numbers displayed in this press release.
Follow us on Twitter: http://twitter.com/zacksresearch
Join us on Facebook: http://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts
Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.
Zacks Investment Research
800-767-3771 ext. 9339